<code id='DB6C0D0A97'></code><style id='DB6C0D0A97'></style>
    • <acronym id='DB6C0D0A97'></acronym>
      <center id='DB6C0D0A97'><center id='DB6C0D0A97'><tfoot id='DB6C0D0A97'></tfoot></center><abbr id='DB6C0D0A97'><dir id='DB6C0D0A97'><tfoot id='DB6C0D0A97'></tfoot><noframes id='DB6C0D0A97'>

    • <optgroup id='DB6C0D0A97'><strike id='DB6C0D0A97'><sup id='DB6C0D0A97'></sup></strike><code id='DB6C0D0A97'></code></optgroup>
        1. <b id='DB6C0D0A97'><label id='DB6C0D0A97'><select id='DB6C0D0A97'><dt id='DB6C0D0A97'><span id='DB6C0D0A97'></span></dt></select></label></b><u id='DB6C0D0A97'></u>
          <i id='DB6C0D0A97'><strike id='DB6C0D0A97'><tt id='DB6C0D0A97'><pre id='DB6C0D0A97'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:9
          illustration of one blue dna strand
          Adobe

          The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

          Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

          advertisement

          Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more
          Obamacare plans could cover weight loss drugs
          Obamacare plans could cover weight loss drugs

          CarstenSnejbjerg/BloombergYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewsletterabou

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog